Mechanism

Evidence tier: 1 — Combination pharmacology characterized in REDEFINE Phase 2 and Phase 3 trials; receptor mechanisms of each component independently validated.

CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (the GLP-1 receptor agonist marketed separately as Wegovy/Ozempic). The therapeutic premise is mechanistic complementarity: GLP-1 receptor agonism drives satiety and slows gastric emptying through the same hindbrain-and-hypothalamic pathway that produces the semaglutide weight-loss signal, while amylin receptor agonism adds a parallel satiety pathway via the area postrema and lateral parabrachial nucleus.

Cagrilintide is a chemically modified analog of human amylin, the pancreatic islet hormone co-secreted with insulin. Native amylin has a half-life of ~13 minutes and self-aggregates; cagrilintide carries lipid-modification and amino-acid substitutions that extend half-life to ~7 days (matching semaglutide's pharmacokinetics for once-weekly co-administration) and prevent fibrillation. It activates amylin and calcitonin receptors and produces dose-dependent appetite suppression and weight loss as monotherapy.

When co-administered with semaglutide, the two mechanisms appear to be additive rather than redundant — the Phase 2 REDEFINE-1 data (PMID 37364590) showed substantially greater weight loss than either component alone. The mechanistic hypothesis is that amylin and GLP-1 act on partially-overlapping but distinct satiety circuits, and dual engagement of both engages a broader fraction of the central regulatory network than either alone.

Typical protocols

Evidence tier: 1 — REDEFINE Phase 2 and Phase 3 dose schedules; no commercial product yet exists.

CagriSema is not yet FDA-approved as of May 2026. The REDEFINE Phase 3 trial program established the registration dose as cagrilintide 2.4 mg + semaglutide 2.4 mg subcutaneously once weekly, matching semaglutide's existing Wegovy dose. Dose-escalation in the trials follows a 16-20 week titration:

Weeks 0-4: 0.25 mg of each component
Weeks 5-8: 0.5 mg
Weeks 9-12: 1.0 mg
Weeks 13-16: 1.7 mg
Week 17+: 2.4 mg maintenance

The trial-evolved protocol mirrors semaglutide's titration schedule because the GI tolerability ceiling is dose-rate-limited. Phase 3 REDEFINE-1 ran 68 weeks; the REDEFINE-2 (T2D) and REDEFINE-3 (cardiovascular outcomes) programs follow similar durations. Compounded CagriSema is not lawfully available through US 503A pharmacies because the molecule lacks FDA approval — community-sourced compounded co-formulations exist but operate outside the FDA-compounding framework that supports semaglutide/tirzepatide.

Evidence by indication

Evidence tier: 1 — REDEFINE-1 Phase 2 NEJM-class publication plus REDEFINE-1 Phase 3 NEJM 2025.

Obesity (REDEFINE-1 Phase 2): The Phase 2 trial in adults with type 2 diabetes (PMID 37364590) showed mean body-weight reduction of 15.6% at 32 weeks on CagriSema vs 5.1% on semaglutide alone and 8.1% on cagrilintide alone — a clear demonstration of mechanistic additivity. HbA1c reduction was 2.2 percentage points on combination therapy.

Obesity (REDEFINE-1 Phase 3): The 68-week Phase 3 trial in 3,417 adults with overweight or obesity (without diabetes) read out in 2025 (PMID 40544433). Mean weight reduction was 22.7% on CagriSema vs 3.0% on placebo, with 40%+ of participants reaching ≥25% weight loss. The effect size sits between tirzepatide (~22% SURMOUNT-1) and retatrutide (~24-29% TRIUMPH series) in the broader weight-loss landscape.

Type 2 diabetes (REDEFINE-2): Phase 3 readout in adults with T2D showed concurrent glycemic and weight-loss benefits, with similar GI tolerability profile to semaglutide monotherapy.

Cardiovascular outcomes (REDEFINE-3 in development): Phase 3 cardiovascular-outcome program parallels the SELECT design (PMID 37952131) that established semaglutide's CV benefit. Readout expected 2027-2028.

The unknowns: durability beyond 68 weeks, long-term safety with sustained dual amylin/GLP-1 engagement, and how the CagriSema effect compares head-to-head with retatrutide's triple-agonist mechanism. The REDEFINE program does not include a head-to-head against retatrutide, and the relative positioning will likely be determined by post-approval real-world data.

Safety profile

Evidence tier: 1 — RCT AE data from REDEFINE-1 and REDEFINE-2; long-term (>2 year) pharmacovigilance not yet available.

The AE profile is dominated by GI events (nausea, vomiting, diarrhea, constipation, abdominal pain) consistent with the GLP-1 class and amplified modestly by the amylin component. In REDEFINE-1 Phase 3, GI events affected 79.6% of CagriSema participants vs 39.9% on placebo; most were mild-to-moderate and concentrated in the titration phase. Discontinuation rates for AEs were similar to semaglutide monotherapy.

Heart-rate elevation (small, 2-4 bpm) is observed, consistent with the GLP-1 class. Pancreatitis signal remains theoretical and is being monitored in Phase 3. No clinically significant amylin-specific safety signal has emerged in the published data — the historical concerns with native amylin (hypoglycemia in insulin-treated diabetics) appear manageable with the cagrilintide pharmacokinetic profile.

Contraindications by analogy with the GLP-1 class: personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, prior severe pancreatitis, severe gastroparesis, pregnancy/lactation.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning in the obesity pharmacotherapy landscape.

In the obesity hierarchy as of May 2026:

Semaglutide (Wegovy, FDA-approved): GLP-1 monoagonist, ~15% weight loss
Tirzepatide (Zepbound, FDA-approved): GLP-1/GIP, ~22% weight loss — current first-line for non-diabetic obesity
CagriSema (Phase 3 complete, awaiting FDA action): GLP-1 + amylin, ~22.7% weight loss
Retatrutide (Phase 3 ongoing): GLP-1/GIP/glucagon, ~24-29% weight loss
Orforglipron (Phase 3, oral): oral non-peptide GLP-1, ~14-15% weight loss

CagriSema's positioning, if approved, will likely be roughly equivalent to tirzepatide on weight-loss magnitude with a differentiated GI tolerability profile and the amylin mechanism as a marketing differentiator. The Retatrutide vs Tirzepatide comparison frames the question of how much additional weight-loss efficacy clinicians will pay for; CagriSema sits in the same competitive zone.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

CagriSema is investigational as of May 2026. Novo Nordisk has not yet filed an FDA NDA; filing is expected on the timeline of the REDEFINE-1 Phase 3 readout, with potential FDA action in 2026-2027. Until approval, lawful access is via clinical trial enrollment only. Compounded CagriSema is not authorized through 503A pharmacy channels because the molecule has no FDA-approved reference product — this is regulatorily distinct from compounded semaglutide (which is based on an FDA-approved molecule and has been compounded under the historical shortage framework). WADA: cagrilintide and semaglutide are both prohibited for athletes regardless of approval status.

References

Frias JP, Deenadayalan S, Erichsen L, et al. 2023. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. PMID 37364590
Garvey WT, Blüher M, Osorto CK, et al. 2025. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. PMID 40544433
Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PMID 37952131
Aronne LJ, Horn DB, le Roux CW, et al. 2025. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PMID 40353578

Limitations

This page does not constitute medical advice. CagriSema should not be used outside a clinical trial in patients with personal/family medullary thyroid carcinoma history, MEN-2, prior severe pancreatitis, severe gastroparesis, or pregnancy/lactation. The Phase 3 readout is recent and the long-term safety profile is not yet fully characterized — we would update our framing on subsequent REDEFINE readouts, FDA action, and post-approval pharmacovigilance. Patients considering CagriSema before approval should pursue clinical trial enrollment rather than research-supplier or compounded supply, both of which sit outside the regulatory framework that supports the existing GLP-1-class options.

CagriSema